Key result
Mild SARS-CoV-2 infection shows no increase in 6-month CMR or biomarker abnormalities versus controls.
Why the study?
Prior CMR studies reported frequent cardiac abnormalities and ongoing myocardial inflammation even after mild, non-hospitalised COVID-19, prompting societal concerns. This study aimed to determine the prevalence and extent of late cardiovascular sequelae following mild non-hospitalised SARS-CoV-2 infection.
Case-Control (n=149)
Blinded analysis
Yes
Answers are grounded in this paper and cite their sources.
No excess cardiac abnormalities 6 months after mild COVID-19; challenges prior screening concerns and leaves open questions in higher-risk populations.
Funding Acknowledgements Type of funding sources: Public Institution(s). Main funding source(s): Barts Charity UCLH Charity OnBehalf COVIDsortium Background Recent CMR studies have reported cardiac abnormalities after COVID-19 are common, even after mild, non-hospitalised illness with evidence of ongoing myocardial inflammation. Such a prevalence of chronic myocarditis after mild disease has prompted societal concerns in diverse domains, and suggests that screening should be considered post COVID-19, even in asymptomatic individuals. Cardiovascular magnetic resonance (CMR) has proven utility for diagnosis in patients with COVID-19 infection and elevated troponin from unclear causes by measuring cardiac structure, function, myocardial scar (late gadolinium enhancement) and oedema (T1 and T2 mapping). Objectives We aimed to determine the prevalence and extent of late cardiac and cardiovascular sequelae after mild non-hospitalised SARS-CoV-2 infection. Methods Participants were recruited from COVIDsortium, a three-hospital prospective study of 731 healthcare workers who underwent first wave weekly symptom, PCR and serology assessment over 4 months, with seroconversion in 21.5% (n = 157). At 6 months post infection, 74 seropositive and 75 age-, sex-, ethnicity-matched seronegative controls were recruited for cardiovascular phenotyping (comprehensive phantom-calibrated Cardiovascular Magnetic Resonance and blood biomarkers). Analysis was blinded, using objective AI analytics where available. Results 149 subjects (mean age 37 years, range 18-63, 58% female) were recruited. Seropositive infections had been mild with case definition/non-case definition/asymptomatic disease in 45(61%), 18(24%) and 11(15%) with one person hospitalised (for 2 days). Between seropositive and seronegative groups, there were no differences in cardiac structure (left ventricular volumes, mass; atrial area), function (ejection fraction, global longitudinal shortening, aortic distensibility), tissue characterisation (T1, T2, ECV mapping, late gadolinium enhancement) or biomarkers (troponin, NT-proBNP). With abnormal defined by the 75 seronegatives (2 standard deviations from mean, e.g. EF < 54%, septal T1 > 1072ms, septal T2 > 52.4ms), individuals had abnormalities including reduced EF (n = 2, minimum 50%), T1 elevation (n = 6), T2 elevation (n = 9), LGE (n = 13, median 1%, max 5% of myocardium), biomarker elevation (borderline troponin elevation in 4; all NT-proBNP normal). These were distributed equally between seropositive and seronegative individuals. Conclusions Cardiovascular abnormalities are no more common in seropositive vs seronegative otherwise healthy, workforce representative individuals 6 months post mild SARS-CoV-2 infection. Our study provides societal reassurance for the cardiovascular health of working-aged individuals with convalescence from mild SARS-CoV-2. Screening asymptomatic individuals following mild diseases is not indicated.
No takes yet. Share an insight, caveat, or question.
Joy et al. (2021) conducted a case-control in Mild SARS-CoV-2 infection (COVID-19) (n=149). Mild SARS-CoV-2 infection (seropositive status) vs. Age-, sex-, ethnicity-matched seronegative controls was evaluated on Prevalence and extent of late cardiac and cardiovascular sequelae on CMR (cardiac structure, function, tissue characterisation) and blood biomarkers. Mild SARS-CoV-2 infection in 74 seropositive healthcare workers showed no difference in CMR or biomarker abnormalities at 6 months compared with 75 matched seronegative controls.
Synapse has enriched 10 related papers. Consider them for comparative context: